Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

PHASE2CompletedINTERVENTIONAL
Enrollment

535

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2018

Study Completion Date

March 31, 2019

Conditions
Myocardial InfarctionAcute Coronary SyndromesUnstable Angina
Interventions
DRUG

Short Tirofiban

25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.

DRUG

Eptifibatide

180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.

DRUG

Long Tirofiban

25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.

Trial Locations (13)

10075

Lenox Hill Hospital, New York

18901

Doylestown Hospital, Doylestown

19104

Penn Presbyterian Medical Center, Philadelphia

23225

Chippenham Hospital, Richmond

30165

Redmond Regional Medical Center, Rome

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital, Atlanta

30501

North Georgia Heart Center, Gainesville

31792

Archbold Medical Center, Thomasville

33709

Northside Hospital, St. Petersburg

34741

Osceola Regional Medical Center, Kissimmee

37203

Centennial Heart, Nashville

73104

University of Oklahoma Health Sciences Center, Oklahoma City

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

SCRI Development Innovations, LLC

OTHER

lead

Medicure

INDUSTRY

NCT01522417 - Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention | Biotech Hunter | Biotech Hunter